Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-11-25 | Dr. Abecassis has been Dean of the University of Arizona College of Medicine – Tucson, and following postgraduate training at the University of Toronto, Dr. Abecassis began his professional career as Assistant Professor of Surgery and Director of Liver Transplantation and Hepatobiliary Surgery. He received his Medical Degree from the University of Toronto in 1983 and was awarded a Master of Business Administration degree from the Kellogg School of Management at Northwestern University in 2000. |
| 2023-06-05 | Michael M. Abecassis (9) 4,471 * Includes 1,670 shares issuable upon the exercise of options to purchase common stock and 2,801 shares upon the vesting of restricted stock units. |
| 2023-07-31 | Michael M. Abecassis - Director, includes 1,670 shares issuable upon the exercise of options to purchase common stock and 2,801 shares upon the vesting of restricted stock units. |
| 2024-03-27 | Dr. Abecassis received his Medical Degree from the University of Toronto and an MBA from Kellogg School of Management. He is a transplant surgeon and researcher. |
| 2025-03-10 | Dr. Abecassis was chosen as a director of the Company because of the combination of his clinical training and experience in HPB diseases, his research background in related areas, and his experience with the regulatory and business aspects of translation and commercialization of research efforts. |
Data sourced from SEC filings. Last updated: 2026-02-03